Cardiovascular Safety of Calcium Supplements

2013 ◽  
pp. 365-372 ◽  
Author(s):  
Ian R. Reid
Keyword(s):  
Cardiovascular Safety ◽  
Calcium Supplements

Overall safety and cardiovascular safety of fixed-dose combination of aclidinium/formoterol compared to salmeterol/fluticasone in patients with COPD

Pneumologie ◽  
2016 ◽  
Vol 70 (S 01) ◽  
Author(s):  
J Beier ◽  
C Vogelmeier ◽  
R Mroz ◽  
S Pascual ◽  
RM Segarra ◽  
...  
Keyword(s):  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Cardiovascular Safety ◽  
Dose Combination

Analysis of adequacy in prescribing calcium supplements based on the daily dairy intake in patients at risk of osteoporosis

2014 ◽  
Author(s):  
Carlos Gomez ◽  
Ana Gomez-Hernandez ◽  
Sonia Sanchez ◽  
Samuel Saez ◽  
Angeles Gonzalez-Carcedo ◽  
...  
Keyword(s):  
At Risk ◽  
Calcium Supplements ◽  
Dairy Intake ◽  
Patients At Risk

Acute effects of calcium supplements on blood pressure: results of a randomised cross-over trial

2016 ◽  
Author(s):  
Sarah Bristow ◽  
Emma Billington ◽  
Greg Gamble ◽  
Kwant Jordyn de ◽  
Angela Stewart ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Acute Effects ◽  
Calcium Supplements

974-P: Network Meta-analysis of Once Weekly Glucagon-Like Peptide-1 Receptor Agonists: A Focus on Cardiovascular Safety and Mortality

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 974-P
Author(s):  
OSAMAH ALFAYEZ ◽  
OMAR A. ALMOHAMMED ◽  
OMAR ALKHEZI ◽  
MAJED S. AL YAMI
Keyword(s):  
Meta Analysis ◽  
Cardiovascular Safety ◽  
Receptor Agonists ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Efficacy and Cardiovascular Safety of Sulfonylureas

2020 ◽  
Vol 15 ◽  
Author(s):  
Cornelius James Fernandez ◽  
Raveendran Arkiath Veettil ◽  
Nyi Htwe
Keyword(s):  
Regulatory Authority ◽  
Microvascular Complications ◽  
Pharmacological Therapy ◽  
Cardiovascular Safety ◽  
Lifestyle Modifications ◽  
First Line ◽  
Considerable Uncertainty ◽  
Cardiovascular Outcome Trials ◽  
Metformin Monotherapy ◽  
Control And Prevention

Abstract:: There is universal agreement that when lifestyle modifications are inadequate to control the hyperglycemia, metformin should be considered as the first line pharmacological therapy. However, when metformin monotherapy fails, there is no consensus as to which drug should be added. Many new classes of drugs that are currently available including DPP-4 inhibitors, GLP-1 agonists and SGLT-2 inhibitors have undergone cardiovascular outcome trials which had been made mandatory by the regulatory authority and thereby established their cardiovascular safety or at least neutrality. Though sulfonylureas are one of the widely prescribed drugs both in developed and developing countries and have proven their efficacy for glycemic control and prevention of microvascular complications, there is considerable uncertainty about its cardiovascular safety which has been going on for nearly five decades. In this review we will critically analyze the efficacy and cardiovascular safety of sulphonylurea, based on the latest available literature to clarify their role in our day-to-day clinical practice.

Sign in / Sign up

Export Citation Format

Share Document